XPA

Across TCGA pan-cancer cohorts, XPA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated XPA data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher XPA mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated XPA expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where XPA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.870	0.628	<.001	31	view →
HNSC	OS	Median	IV	0.881	0.583	.001	31	view →
CCRCC	DFS	Median	III,IV	0.985	0.144	.008	27	view →
PDAC	OS	Quartile	III,IV	1.000	0.472	.013	11	view →
LSCC	DFS	Tertile	All	1.000	0.480	.018	3	view →
GBM	DFS	Tertile	All	0.865	0.694	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

XPA–LUAD (OS)

Open the LUAD breakdown →